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Abstract
Our aim was to evaluate correlation between clinicopathological features (clinical T and clinical N stages; histological type;
nuclear grade; hormone-receptor and HER2 status, proliferation activity and tumor subtypes) of breast cancer and kinetic
parameters measured by staging dynamic FDG-PET/CT examinations. Following ethical approval and patients’ informed con-
sent we included 34 patients with 35 primary breast cancers in our prospective study. We performed dynamic PET imaging, and
assessed plasma activity noninvasively. To delineate primary tumors we applied a frame-by-frame semi-automatic software-
based correction of motion artefacts. FDG two-compartment kinetic modelling was applied to assess K1, k2, k3 rate coefficients
and to calculate Ki (tracer flux constant) and MRFDG (FDG metabolic rate). We found that k3, Ki and MRFDG were signif-
icantly higher in higher grade (p = 0.0246, 0.0089 and 0.0076, respectively), progesterone-receptor negative (p = 0.0344, 0.0217
and 0.0132) and highly-proliferating (p = 0.0414, 0.0193 and 0.0271) tumors as well as in triple-negative and hormone-receptor
negative/HER2-positive subtypes (p = 0.0310, 0.0280 and 0.0186). Ki and MRFDG were significantly higher in estrogen-
receptor negative tumors (p = 0.0300 and 0.0247, respectively). Ki was significantly higher in node-positive than in node-
negative disease (p = 0.0315). None of the assessed FDG-kinetic parameters showed significant correlation with stromal TIL.
In conclusion, we confirmed a significant relationship between kinetic parameters measured by dynamic PET and the routinely
assessed clinicopathological factors of breast cancer: high-grade, hormone-receptor negative tumors with high proliferation rate
are characterized by higher cellular FDG-uptake and FDG-phosphorylation rate. Furthermore, we found that kinetic parameters
based on the dynamic examinations are probably not influenced by stromal TIL infiltration.
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MRFDG FDG metabolic rate in the tissue,
μmol/min/100 g tissue
OSEM Ordered subsets expectation maximization
PR Progesterone receptor
SD Standard deviation
SE-TUKEB Semmelweis University Institutional
Review Board
SUV Standardized Uptake Value
TAC Time-activity-curve
TIL Tumor infiltrating lymphocytes
TNBC Triple negative breast cancer
VOI Volume of interest
Introduction
In locally advanced breast cancer current guidelines suggest 2-
deoxy-2[18F]fluoro-D-glucose positron emission tomography
and computer tomography (FDG-PET/CT) as a useful and ac-
curate tool for staging. Additionally, its role is also emerging in
the response evaluation during neoadjuvant therapies [1]. Most
commonly PET/CT scans are evaluated semi-quantitatively:
the amount of the accumulated radiotracer is measured at one
predefined time-point after injection (i.e. static imaging) and
characterized by the calculated Standardized Uptake Value
(SUV). SUV shows strong correlation with the clinicopatho-
logical characteristics of breast cancer, such as histological tu-
mor type, biological subtype, grading and proliferation rate [2,
3]. Nonetheless, the static nature of SUV measurement can
introduce several sources of bias, most importantly it is highly
dependent on the time elapsed from tracer injection as well as
body composition and glucose-metabolism of the patient [4].
These limitations of the SUV parameter could cause several
bias during the staging and response evaluation. Therefore, in
our current study we used dynamic PET imaging to accurately
quantify the radiotracer uptake by the kinetic analysis of FDG-
accumulation over a period of time.
In case of dynamic breast PET imaging, data collection
lasted constantly for 60 min, right directly after the tracer injec-
tion. The compartment modelling of FDG-distribution is used
to evaluate the data acquired by dynamic imaging. Using the
FDG-two-compartment model we could estimate the important
rate parameters of the tracer flow between the blood-pool (first,
plasma compartment) and the investigated tissue compartments
(i.e. a transfer compartment, where FDG is intracellular and a
metabolic compartment where FDG is in FDG-6-phosphate
form). The estimated rate constants describe the influx and
efflux of the FDG between these compartments: K1 and k2
are the rate constants representing carrier-mediated transport
of FDG from plasma to tissue (K1) and back from tissue to
plasma (k2), in the transfer compartment. k3 represents the rate
constant for phosphorylation of the FDG by the hexokinase
enzyme in the metabolic compartment. Based on the above
listed parameters the net tracer influx constant [Ki = (K1*k3) /
(k2 + k3)] could be calculated. [5, 6].
We aimed to investigate the possible role of dynamic im-
aging in the characterization of breast cancer during the initial
clinical staging. We assessed the correlations between the ki-
netic parameters measured by dynamic PETexaminations (i.e.
K1, k2, k3, Ki) and the routinely used predictive and prog-
nostic factors of breast cancers − such as clinical TNM, histo-
logical tumor type, tumor grade, proliferation rate and receptor
status (i.e. hormone-receptor (HR) and human epidermal
growth factor receptor 2 (HER2) expression). We also defined
the clinical subtypes of the tumors, due to their important role
in therapeutic choices in the daily practice [7]. Moreover, a
novel pathological marker was also assessed in our study: the
presence of tumor infiltrating lymphocytes (TIL) in the stroma
of the tumors. Immune-cells are playing a central role in shap-
ing of tumor microenvironment and presence of TILs proved
to be a possible prognostic factor for favorable clinical out-
come by itself [8]. Additionally, the lymphocyte predominant
subgroups of triple negative tumors and hormone-receptor
negative and HER2-positive (HR-/HER2+) tumors show a
favorable response to systemic therapy, but, interestingly, this
is not the case in hormone-receptor positive breast cancers.
TIL could also have a future role to predict the effectiveness
of immunotherapies [8]. In our study we tried to investigate if
there is a connection between the presence of TILs and the
measured FDG-influx during dynamic PET examinations.
In summary, in our current paper we present the results of
our study with dynamic FDG-PET/CT imaging used in the
staging of breast cancer. Our focus is on – over the routinely
assessed clinicopathological characteristics of breast tumors –
the rarely investigated correlations between tumor phenotype
and FDG-kinetics, with special emphasis on clinical subtypes
and tumor microenvironment (characterized by stromal TILs).




In our prospective study we included patients with invasive
breast cancer. The inclusion criteria were the same as in our
earlier published study [9], as follows: 1) diagnosis of primary
breast cancer confirmed by core biopsy; (2) patients who were
referred to the multidisciplinary tumor board of Semmelweis
University Oncology Center in whom the board acknowl-
edged the need of whole-body staging by using FDG-PET/
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CT; (3) only tumors of at least 20mm (T1c≤) were included to
avoid the negative impact of partial volume effect in case of
smaller lesions [10]; (4) patients with ECOG performance
status 0 or 1 and age above 18 years; (5) signed written in-
formed consent form.
Patients were excluded from the current analysis if: (1) any
distant metastasis of parenchymal tissues was confirmed by
staging FDG-PET/CTexaminations (the presence of boneme-
tastases was permitted); (2) chemotherapy was already initiat-
ed or radiation therapy was applied previously in the region of
the affected breast; (3) inflammatory breast cancer; (4) preg-
nant or breast feeding patients; (5) claustrophobia; (6) patients
who were not able or did not want to lie still for 60 min during
the examination – especially with known co-morbidities
which interfere with the need of prolonged immobility
(Parkinson disease, musculoskeletal disorders etc.); (7) if a
peripheral venous access could not be ensured. Only those
patients can be considered for dynamic PETwho are capable
of successful cooperation during the whole, prolonged time of
the imaging procedure.
Clinical TNM (cTNM stages) was assessed by using rou-
tinely applied diagnostic imaging modalities (X-ray and ultra-
sound mammography, and FDG-PET/CT) according to
American Joint Committee on Cancer (AJCC) TNM 8th
guideline [11].
Ethical approval for the study was given by the
Semmelweis University Institutional Review Board (SE-
TUKEB No.119/2013; date of approval: 24 June 2013).
Every patient was informed personally and written informed
consent form was signed by them before the enrollment.
Histopathological Analysis
Formalin-fixed, paraffin-embedded pre-treatment core biopsy
samples were examined at the Semmelweis University 2nd
Department of Pathology, by board-certified pathologists.
Detailed histological characterization was performed on the
core biopsy samples, including the determination of histolog-
ical type and nuclear grade. Immunohistochemistry (IHC) was
routinely performed to evaluate hormone receptor – estrogen
(ER) and progesterone (PR) – status, as well as HER2 expres-
sion according to international guidelines, with the evalua-
tions of tumor proliferation by using the Ki-67 labeling index
(Ki-67 LI).
Hormone receptor positivity was confirmed if Allred score
was above or equal to 3 [12]. HER2 overexpression was de-
fined as IHC 3+. HER2 1+ or 0 tumors were consideredHER2
negative. For IHC 2+ samples, fluorescent in situ hybridiza-
tion (FISH) was performed to confirm gene amplification.
HER2 status was defined according to the American Society
of Clinical Oncology/College of American Pathologists
(ASCO/CAP) Guideline valid at the time of diagnosis, i.e.
HER2-positive patients treated between January 2008 and
November 2013 were identified according to the 2007
ASCO/CAP Guideline [13] and from then on according to
the Guideline published in October 2013 [14]. Ki-67 LI was
scored as described by Dowsett et al. [15, 16]: every slide was
assessed visually and the proportion of positive cells was de-
termined by counting approximately 500 tumor cells at 400x
magnification. For Ki-67 LI a cell was considered positive if
any nuclear signal was observed, similar to the earlier pub-
lished studies of Tőkés et al. [17].
Biological subtype of the tumors was defined according to
the recommendations of the 2017 St. Gallen International
Breast Cancer Conference [7]. Triple negative (TNBC),
hormone-receptor negative and HER2-positive (HR-/HER2+
), hormone-receptor positive and HER2-positive (HR+/
HER2+) and hormone-receptor positive and HER2-negative
(HR+/HER2-) tumors were separated based on the expression
of ER, PR and HER2, taking into account the Ki-67 LI status,
as well.
Additionally, the core-biopsy samples were also evaluated
for the presence of tumor infiltrating lymphocytes (TIL) in the
stroma of the tumors, according to the TILs Working Group
guideline published in 2015 [8]. Evaluation of the stromal
TILs was performed by co-authors TAM and JK, experts of
the field.
PET/CT Studies
All PET examinations were performed with Siemens
Biograph TruePoint 6 HD (Siemens Molecular Imaging
Division, Knoxville, USA) PET/CT scanner. Patients were
prepared according to standard guidelines [18, 19]. Most
importantly, the examinations were preceded by at least 6-
hour starvation. The level of blood glucose and body-weight
were measured upon arrival to the PET/CT Center. The av-
erage weight of the investigated patients (n = 34) was 67.7 ±
12.5 kg and the mean blood glucose was 5.1 ± 0.9 mmol/L.
The scans were acquired after the intravenous injection of
155.4–384.8 MBq (4.2–10.4 mCi) FDG according to body
weight (~3.7 MBq/kg; ~0.1 mCi/kg). The mean dose of ad-
ministered FDG was 254.6 ± 51.9 MBq (6.8 ± 1.4 MBq).
Intravenous injection of tracer was performed with the pa-
tient lying on the examination table (minute zero). PET data
collection was continuous (list mode) from minute zero, with
fixed bed position over the chest region (Z axis length:
21.6 cm). Dynamic PET data acquisition lasted for 60 min,
with the patient lying still on the examination table of the
PET/CT scanner. The dynamic imaging sequence, starting
with the initiation of the bolus was 8 × 15 seconds, 8 × 30
seconds, 2 × 60 seconds, 3 × 2 minutes, 4 × 3 minutes, 1 × 4
minutes and 6 × 5 minutes. PET images were corrected for
decay, attenuation and normalization, scatter and randoms
rejection, as well as for dead time. PET data were acquired
in three-dimensional mode and were reconstructed using CT
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data for attenuation correction with ordered subsets expecta-
tion maximization (OSEM) algorithm (4 iterations, 8 sub-
sets), using a 168x168x74 image matrix with voxel dimen-
sion of 4.07 × 4.07 × 3.0 mm. Image reconstruction was per-
formed as described earlier in our previous study [9]: the
early frames of every dynamic study (from 1 to 4, from 5
to 8, from 9 to 10 and from 11 to 12 frames, respectively)
was averaged in a time-weighted manner (which process is
offered by most of the available software tools) to correct the
earlier described inaccuracies without significant degradation
of time resolution.
Collected dynamic data were analyzed by using PMOD
software (v3.310, Zürich, Switzerland). Every study was
assessed by the same two experienced observers (KK and
TT). To generate the time-activity-curves (TACs), changes
of activity concentrations were assessed in the tumor and in
the blood pool (i.e. plasma). To assess plasma activity,
observers draw a sphere volume of interest (VOI) in the
left ventricle (LV) of the heart sized 15 mm in diameter.
Similarly, 15 mm sized sphere VOIs were also used to
measure the primary tumors’ activity over time. To elimi-
nate movement artefacts due to involuntary movements
and breathing, positions of the VOIs were corrected by
using a semi-automatic, computer-assisted method, pub-
lished earlier [9]: at first we placed a VOI over the tumor,
which exceeded the longest diameter of the examined le-
sion with at least 10 mm, and then we centered the VOI to
the voxel with the highest uptake in the target region. By
reducing the size of the VOI to 15 mm in diameter, we
finalized the motion correction of the current time-frame.
This procedure was repeated on every time-frame of the
dynamic studies. This approach seemed to be reliable, re-
producible, with low inter-observer variability, compared
to manual motion correction [9].
Thereafter TACs were defined by using the VOIs of left
ventricle and the tumor(s), afterwards FDG two-compartment
kinetic modelling (non-reversible, k4 = 0) was applied to as-
sess K1, k2, k3 coefficients and to calculate Ki and MRFDG
(the FDG metabolic rate in the tissue, μmol/min/100 g tis-
sue). Relationship of these parameters is defined by the fol-
lowing equation:
MRFDG ¼ Cglcx Ki
where Cglc is the blood glucose level of the patient measured
right before the initiation of the dynamic PET imaging. It
should be highlighted that MRFDG is not equivalent to the
glucose metabolic rate (referred as MRGlu), since the con-
stant which describes the relationship between the FDG ac-
cumulation and glucose consumption (i.e. the lumped con-
stant) is not defined yet in case of breast tissues - therefore the
exact rate of the glucose metabolism cannot be calculated
reliably [5, 20].
Statistical Analysis
Data were expressed as mean ± standard deviation (SD) or
median and lower interquartile-upper interquartile (LIQ-
UIQ). All applied statistical tests were two-sided and p-
values<0.05 were considered significant. Shapiro-Wilks test
was applied to test the normality of the data. Connections
between clinicopathological characteristics and the kinetic pa-
rameters were assessed by using Mann-Whitney and Kruskal-
Wallis tests.
For data collection and processing we used Microsoft
Excel 2010 (Microsoft Corporation, Redmond Washington,
USA), Statistica v13.2 (StatSoft Inc.) and SPSS v22.0 (IBM
Corporation) software.
Results
A total of 35 lesions detected during 34 dynamic studies were
included in this current analysis. Dominantly grade 3 (19/35;
54%) invasive breast carcinomas of no special type (IBC
NST) (30/35; 85.7%) were evaluated. 24 of the included tu-
mors were ER positive (69%) and 22 were PR positive (63%)
(total number of hormone receptor positive (HR+) lesions was
25 – one lesion showed solely PR positivity, but ER negativ-
ity). Only six tumors showed HER2 positivity (17%) and 27
tumors showed elevated proliferation activity, i.e. Ki-67 LI >
20% (77%). (Table 1).
Regarding clinical subtypes of the investigated lesions,
eight tumors were TNBC (22.9%) and 2 were HR-/HER2+
(5.7%). 4 tumors were HR+/HER2+ (11.4%). The remaining
21 lesions were HR+/HER2-. Amongst these, five were lumi-
nal A-like tumor (14.3%), seven were luminal B-like (20%)
and 9 lesions belonged to the intermediate subgroup (25.7%).
We analyzed the relationship between the kinetic parameters
measured on the dynamic PET/CTs and the known predictive
and prognostic factors (i.e. clinical T and clinical N stages; his-
tological type; nuclear grade; ER, PR andHER2 status, Ki-67 LI
and tumor subtype) in pre-therapy core-biopsies (Table 2).
We did not find significant differences according to tumor
size (clinical Tcategories). However, in case of nodal involve-
ment Ki was significantly higher in node positive than in node
negative disease (p = 0.0315).
Tumorswith higher nuclear grade showed significantly higher
k3 (p= 0.0246), Ki (p= 0.0089) and MRFDG (p= 0.0076).
Regarding hormone receptor status, we found that Ki (p =
0.0300 and p = 0.0217, respectively) and MRFDG (p =
0.0247 and p = 0.0132, respectively) were significantly higher
in ER negative and PR negative tumors than in hormone re-
ceptor positive (HR+) cancers. In PR negative tumors, k3 was
also significantly higher compared to PR positive lesions (p =
0.0344). HER2 status did not show any correlation with the
kinetic parameters. Tumors with elevated Ki-67 LI (i.e. high
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proliferation activity) showed significantly higher k3 (p =
0.0414), Ki (p = 0.0193) and MRFDG (p = 0.0271).
Additionally, FDG-kinetics were also compared between
the St. Gallen 2017 consensus [7] based clinical subtypes.
Initially, we did not find significant differences between the
clinical subtype distribution of the tumors and the investigated
kinetic parameters. However, considering the low number of
cases present in each clinical subtype, we performed an addi-
tional analysis: subgroups were compared based on their prog-
nostic significance - more aggressive TNBC and HR-/HER2+
subtypes (n = 10) were compared with hormone-receptor pos-
itive lesions (HR+/HER2+ and HR+/HER2- tumors, n = 25).
TNBC and HR-/HER2+ subtypes showed significantly higher
k3 (p = 0.0310), Ki (p = 0.0280) and MRFDG (p = 0.0186)
compared to hormone-receptor positive diseases.
In summary, three kinetic parameters (k3, Ki and
MRFDG) were strongly associated with the biological be-
havior of the tumors. The correlations between k3, Ki and
MRFDG and tumor grade, ER and PR status, Ki-67 LI and
subtype groups are presented on Figs. 1, 2, and 3. All of
these correlations were significant except the correlation
between k3 and ER status.
We also analyzed the correlations between the presence of
stromal TILs and kinetic parameters of the primary tumors.
Data about the presence TIL was available in 23 patients.
Median TIL was 5% (LIQ-UIQ:1–7.5%), most of the lesions
showed slightly elevated but not significantly high stromal
TIL content (12/23 lesions showed TIL between 1% and
20%). Every investigated kinetic parameter was higher in tu-
mors with TIL infiltration >1% and higher K1 and k2 was
measured in tumors with increased TIL (>20%), but none of
these observations were statistically significant (Table 2).
Discussion
In breast cancer, the routinely used predictive and prognostic
(bio)markers are mainly based on invasive tumor sampling
and pathological assessment (i.e. tumor type, grade, prolifer-
ation activity, receptor status etc.). The relationship between
these markers and FDG-avidity measured during static FDG-
PET/CT imaging is already known and substantially investi-
gated [2, 3]. Amongst others, our research group already
highlighted the strong relationship between SUV and several
clinicopathological factors of breast cancer: lesions with IBC-
NST phenotype showing high-grade features and increased
proliferation, with triple negativity and axillary lymph node
positivity usually show higher FDG-uptake compared to low-
grade, luminal A-like tumors with node negativity [2, 3].
On the contrary, the role of dynamic PET imaging is under
debate in breast cancer. The indisputable advantage of dynam-
ic FDG-PET/CT is its capability to accurately quantify FDG-
uptake. Therefore, dynamic imaging carries a potential to
Table 1 Clinicopathological characteristics (n = 34 patients with
n = 35 lesions)







cN positivity (cN1–3) 25 73.5
Clinical M stage
cM0 33 97
cM1 * 1 3
Pathological Characteristics (n = 35 lesions) No. %
Histology
IBC-NST 30 85.7
Invasive lobular carcinoma 2 5.7






ER positive 24 68.6
ER negative 11 31.4
Progesterone receptor status
PR positive 22 62.9
PR negative 13 37.1
HER2 status
HER2 positive 6 17.1
HER2 negative 29 82.9
Proliferation rate
High Ki-67 LI 27 77.1
Low Ki-67 LI 8 22.9
Clinical subtypes#
Triple negative (TNBC) 8 22.9
HR-/HER2+ 2 5.7
HR+/HER2+ 4 11.4
HR+/HER2-: Luminal A-like tumors 5 14.3
HR+/HER2-: Intermedier subgroup 9 20
HR+/HER2-: Luminal B-like tumors 7 25.7
*1 patient was included with bone metastases on the initial staging
†two invasive pleiomorph carcinoma, one undifferentiated adenocarcino-
ma of the breast
‡in 6 patients tumor grade is unknown . # 1 patient has a PR-positive but
ER-negative tumor, therefore the overall number of HR+ lesions is 25
Abbreviations: IBC NST invasive breast carcinomas of no special type,
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal
growth factor receptor 2, Ki-67 LI Ki-67 labeling index, HR-/HER2+
hormone-receptor negative and HER2-positive, HR+/HER2+ hormone-
receptor positive and HER2-positive,HR+/Her2- hormone-receptor pos-
itive and HER2-negative
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define novel predictive and prognostic biomarkers in vivo for
numerous tumor types. The assessment of the correlations
between in vivo measured parameters of FDG tracer kinetics
and biological behavior of breast tumors can increase the val-
ue of dynamic PET/CT imaging in the daily practice.
However, implementation of dynamic PET imaging is com-
plicated, time- and resource-consuming; therefore, the delin-
eation of a suitable patient population is essential. A few stud-
ies already investigated the role of the parameters derived
from dynamic data collection followed by tracer kinetic
Table 2 Relationship between the clinicopathological characteristics of the investigated breast tumors and the kinetic parameters of the performed
dynamic PET examinations











T1c (4) 0.185 0.543 0.062 0.018 8.701
T2 (26) 0.375 1.095 0.099 0.036 17.531
T3 (5) 0.258 0.779 0.164 0.044 23.292
p value 0.3742 0.9003 0.2206 0.0834 0.0780
Clinical N stage
N0 (9) 0.292 0.909 0.076 0.023 12.961
N1–3 (26) 0.352 1.014 0.114 0.039 18.862
p value 0.5459 0.2271 0.2575 0.0315 0.1046
Histology *
IBC-NST (30) 0.337 1.004 0.101 0.034 16.951
other (5) 0.333 0.884 0.125 0.041 19.709
Nuclear grade †
1 (2) 0.149 0.427 0.049 0.015 6.148
2 (8) 0.353 0.983 0.071 0.022 10.838
3 (19) 0.371 1.157 0.129 0.042 21.875
p value 0.3075 0.3417 0.0246 0.0089 0.0076
ER status
positive (24) 0.279 0.727 0.094 0.032 14.934
negative (11) 0.462 1.555 0.128 0.041 22.604
p value 0.4095 0.5872 0.0667 0.0300 0.0247
PR status
positive (22) 0.277 0.735 0.088 0.029 13.775
negative (13) 0.436 1.414 0.132 0.044 23.386
p value 0.2035 0.5782 0.0344 0.0217 0.0132
HER2 status
positive (6) 0.369 1.136 0.104 0.033 15.824
negative (29) 0.329 0.956 0.105 0.035 17.659
p value 0.5933 0.2184 0.4801 0.8814 0.9151
Ki-67 LI
low (8) 0.269 0.802 0.062 0.021 9.931
high (27) 0.356 1.042 0.117 0.039 19.542
p value 0.8323 0.9843 0.0414 0.0193 0.0271
Subtype
Triple negative (8) 0.456 1.602 0.134 0.043 23.844
HR-/HER2+ (2) 0.674 2.087 0.136 0.041 21.863
HR+/HER2+ (4) 0.217 0.661 0.088 0.029 12.804
HR+/HER2- (21) 0.281 0.710 0.093 0.032 15.303
p value (all) 0.1932 0.2396 0.1666 0.1865 0.1374
p value (TNBC and HER2+ vs. all HR+) 0.1514 0.2703 0.0310 0.0280 0.0186
TIL‡
TIL ≤1% (8) 0.225 0.483 0.089 0.033 15.346
1%< TIL <20% (12) 0.347 1.023 0.109 0.036 18.807
TIL ≥20% (3) 0.742 2.916 0.095 0.032 16.048
p value (all) 0.4713 0.0940 0.2055 0.5849 0.4346
p values: in bold. Underlined: statistically significant difference
*Due to low case numbers and statistical power we did not perform a statistical comparison;
† Missing in case of 6 tumors; ‡ missing in case of 12 tumors
Abbreviations: IBC NST invasive breast carcinomas of no special type, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth
factor receptor 2, Ki-67 LI Ki-67 labeling index, TNBC triple negative, HR−/ HER2+ hormone-receptor negative and HER2-positive, HR+/ HER2+
hormone-receptor positive and HER2-positive, HR+/ HER2+ hormone-receptor positive and HER2-negative, TIL tumor infiltrating lymphocytes
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modelling in the staging of breast cancer [21] as well as during
response evaluation to neoadjuvant therapy [20–27]. Our
study focused on the rarely investigated correlations between
tumor phenotype and FDG-kinetics, with special emphasis on
clinical subtypes and tumor microenvironment (characterized
by stromal TILs), which has gained special attention in recent
years of cancer research.
In our study, while analyzing core-biopsy samples of breast
cancer, we did not find any correlation between lesion size and
the kinetic parameters of the dynamic PET studies. If axillary
lymph node status was positive per clinical-imaging investiga-
tions (>cN0), every measured kinetic parameter was higher
compared to clinically node-negative (cN0) cases, but the rela-
tionship was only significant in case of Ki. Dunnwald et al.
described similar results in their earlier published study regard-
ing Ki, but they found that K1 is also significantly higher in
node positive disease (nonetheless, they did not published any
results particularly about the correlations with k2 and k3) [21].
Regarding the biological characteristics of the assessed
breast cancers, we found that every assessed kinetic parameter
was elevated in high-grade tumors and this correlation was
statistically significant in case of k3, Ki and MRFDG. When
assessing the correlation with tumor proliferation, similar cor-
relations were found: lesions with high Ki-67 LI showed sig-
nificantly higher values of k3, Ki and MRFDG compared to
lesions characterized by low Ki-67 LI. Dunnwald et al. found
the same significant correlations for Ki. They also assessed the
relationship between Ki-67 LI and K1, but did not find a
significant correlation with tumor grade or proliferation (it is
note that they did not evaluate the role of k2 nor k3) [21].
Regarding hormone receptor status, significantly different
FDG-kinetic parameters were detected in HR- tumors com-
pared to HR+ lesions. In case of ER expression, Ki and
MRFDG were significantly higher in ER-negative than in
ER-positive lesions. Regarding PR the k3, Ki and MRFDG

















































































a b c d e
Fig. 1 Box-plot figures representing the comparison of k3 values
between (a) grade 1, grade 2 and grade 3 tumors (p=0.0246); (b)
estrogen (ER) positive(+) and ER negative(−) tumors (p=0.0667); (c)
progesterone (PR) positive(+) and PR negative(−) tumors (p=0.0344);
(d) tumors with high and low Ki-67 LI (p=0.0414). We also compared
the value of k3 between two patient groups based on biological subtypes
(e): the more aggressive TNBC and HR-/HER2+ subtypes(group 1) and
the hormone-receptor positive lesions (HR+/HER2+ and HR+/HER2-
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Fig. 2 Box-plot figures representing the comparison of Ki values
between (a) grade 1, grade 2 and grade 3 tumors (p=0.0089); (b)
estrogen (ER) positive(+) and ER negative(−) tumors (p=0.0300); (c)
progesterone (PR) positive(+) and PR negative(−) tumors (p=0.0217);
(d) tumors with high and low Ki-67 LI (p=0.0193). We also compared
the value of Ki between two patient groups based on biological subtypes
(e): the more aggressive TNBC and HR-/HER2+ subtypes(group 1) and
the hormone-receptor positive lesions (HR+/HER2+ and HR+/HER2-
tumors) (group 2) (p=0.0028)
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tumors. In our study, we did not find a significant correlation
between HER2 positivity and the investigated kinetic param-
eters of the dynamic studies. Nonetheless, the group of TNBC
and HR-/HER2+ subtypes showed significantly higher values
of k3, Ki and MRFDG in comparison to hormone-receptor
positive breast cancers (i.e. HR+/HER2+ and HR+/HER2-
tumors). Regarding hormone-receptor and HER2-status simi-
lar correlations were published earlier by Dunnwald et al. as
was observed in our study, but only in case of Ki [21]. The
analysis of the relationship between breast cancer subtypes
and FDG-kinetics was not performed earlier, only in case of
static PET/CT imaging, where similar correlations were de-
scribed [2, 3]. In our study TNBC and HR-/HER2+ subtypes -
which are characterized by worse clinical outcome compared
to hormone-receptor positive (HR+) tumors – are confirmed
to have high FDG-influx and a more prominent FDG meta-
bolic rate, which explains the significantly higher SUVs of
these phenotypes during routine static PET imaging [2, 3].
We also assessed the ratio of stromal TILs in the primary
tumors, due to its possible prognostic and predictive role in
breast cancer [8]. It is reasonable to hypothesize that tumor
microenvironment - especially the amount of stromal TILs -
could affect the FDG uptake and distribution of malignant le-
sions. In gastric cancer [28] and in case of non-small cell lung
cancer [29] a positive correlation was already described be-
tween the presence of TILs and FDG-uptake in case of routine-
ly used static FDG-PET/CT imaging. Regarding breast cancer,
this question was only assessed indirectly, in the recently pub-
lished study of Fujii et al. [30], who found a relationship be-
tween higher neutrophil granulocyte/lymphocyte ratio (i.e. a
marker of systemic inflammation) and higher-FDG uptake (also
evaluated during static imaging). Nevertheless, in our study we
did not find significant difference in the kinetic parameters of
the dynamic studies when compared breast tumors with differ-
ent ratios of stromal TILs. Our preliminary results suggest that
the presence of stromal TILs did not affect significantly the
measured FDG-kinetics of the dynamic studies in breast cancer
patients – however this hypothesis must be further investigated
by repeating our study in a larger group of patients.
Based on the above, we can highlight that the same corre-
lations can be found between the kinetic parameters of the
dynamic PET examinations and breast tumors’ phenotype as
were described earlier when only static FDG-PET/CT imag-
ing was used in the staging of breast cancers [2, 3]. During
dynamic imaging high-grade, hormone-receptor negative tu-
mors with high proliferation rate are characterized by higher
cellular FDG-uptake and FDG-phosphorylation rate (in har-
mony with earlier published results [21]). These lesions are
showing significantly higher SUVs if static FDG-imaging is
applied for staging [2, 3]. Nevertheless, these tumors frequent-
ly present as locally advanced diseases with aggressive clini-
cal behavior, therefore are regularly treated with neoadjuvant
therapy. In this case, the limitations of the SUV parameter of
static imaging could cause several bias during the response
evaluation. For example if the patient lost significant body-
weight during the therapeutic course or had altered renal clear-
ance due to the applied chemotherapies the value of the SUV
could be diverged accordingly [4]. Dynamic imaging however
is capable to accurately quantify the FDG-uptake and it is not
affected by these bias. For this reason, testing of dynamic PET
has already been begun in this specific indication [20–27].
Based on these earlier studies we can conclude that an initially
high rate of FDG-influx and lower MRFDG as well as a lower
post-therapeutic Ki and K1 are both predictive to favorable
tumor response to the neoadjuvant therapy [21–25]. These
result are probably related to the strong correlations between
the value of Ki and tumor vascularization [23], blood flow
[24] and functional tumor volume [26], which parameters
are suitable to delineate residual disease, if still onset after
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Fig. 3 Box-plot figures representing the comparison of MRFDG values
between (a) grade 1, grade 2 and grade 3 tumors (p=0.0076); (b) estrogen
(ER) positive(+) and ER negative(−) tumors (p=0.0247); (c) progesterone
(PR) positive(+) and PR negative(−) tumors (p=0.0132); (d) tumors with
high and low Ki-67 LI (p=0.0271). We also compared the value of
MRFDG between two patient groups based on biological subtypes (e):
the more aggressive TNBC and HR-/HER2+ subtypes(group 1) and the
hormone-receptor positive lesions (HR+/HER2+ and HR+/HER2- tu-
mors) (group 2) (p=0.0186)
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seems likely that response evaluation with the kinetic param-
eters of the dynamic studies is not depending on the initial pre-
therapy FDG-uptake as much as the static evaluations (using
the SUV) is. With dynamic imaging the follow-up of less
FDG-avid breast tumors, with lower pre-therapy FDG-uptake
can also be implemented [21, 22, 27].
Thus, based on our results, in the staging of breast cancer
dynamic imaging may not have an outstanding added value
due to its similar correlations with the clinico-pathological
characteristics of the tumors which has already been described
by static imaging studies. However, our current results are
suggesting that if tumor microenvironment is taken into ac-
count, it seems likely that the parameters of dynamic imaging
are not affected by TIL ratio as much as the routinely applied
static imaging. Additionally, based on earlier preclinical and
clinical studies, if neoadjuvant chemotherapy is planned in
locally advanced disease, dynamic imaging could be a prom-
ising tool for response evaluation, by quantifying FDG-uptake
more precisely when initial staging and post-therapy imaging
is compared. Our next studies are addressed to further enlight-
en its role in the clinical routine.
The main limitations of our study is our VOI delineation
method: the reported kinetic parameters only describing a
15 mm sized portion of the investigated tumors instead of
the whole, sometimes heterogeneous tumor mass.
Additionally, during motion correction the VOIs were cen-
tered on the most metabolically active part of the lesions,
which could also be misleading, especially in large lesions.
Additionally, the small number of tumors in which TIL was
determined (only in 65% of the included patients) is also lim-
iting the value of our results. To further clarify the correlation
between tumor microenvironment and FDG-kinetics, our
study must be repeated in larger group of patients.
In conclusion, our preliminary findings proved a significant
relationship between kinetic parameters measured by dynamic
PET and the routinely assessed clinicopathological factors,
similarly as was known in case of static SUV measurements.
We also confirmed that high-grade, hormone-receptor nega-
tive tumors with high proliferation rate are characterized by
higher cellular FDG uptake and FDG phosphorylation rate
based on dynamic imaging. Additionally, we further
underlined the aggressive biological behavior of TNBC and
HR-/HER2+ subtypes. Furthermore, we described that kinetic
parameters measured by dynamic PETexaminations are prob-
ably not influenced by stromal TIL infiltration.
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